Predicted protein targets (top 14)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | GAA | P10253 | 3/20 | 0.72 |
| ▸ | KMT2A | Q03164 | 4/20 | 0.68 |
| ▸ | ALDH1A1 | P00352 | 1/20 | 0.62 |
| ▸ | CYP1A2 | P05177 | 1/20 | 0.62 |
| ▸ | CYP3A4 | P08684 | 1/20 | 0.62 |
| ▸ | CYP2C9 | P11712 | 1/20 | 0.62 |
| ▸ | CYP2C19 | P33261 | 1/20 | 0.62 |
| ▸ | MAPK1 | P28482 | 2/20 | 0.57 |
| ▸ | MAPT | P10636 | 2/20 | 0.57 |
| ▸ | HTT | P42858 | 2/20 | 0.57 |
| ▸ | POLB | P06746 | 1/20 | 0.57 |
| ▸ | MEN1 | O00255 | 2/20 | 0.56 |
| ▸ | RAB9A | P51151 | 1/20 | 0.56 |
| ▸ | LMNA | P02545 | 1/20 | 0.56 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL4076916 | 0.89 | LMNA (0.62) | GAAKMT2AALDH1A1CYP1A2CYP3A4 | |
| SCHEMBL6494581 | 0.85 | GAA (0.66) | GAAKMT2AALDH1A1MAPK1MAPT | |
| SCHEMBL7293057 | 0.84 | LMNA (0.72) | GAAKMT2AALDH1A1CYP1A2CYP3A4 | |
| SCHEMBL31556370 | 0.84 | LMNA (0.72) | GAAKMT2AALDH1A1CYP1A2CYP3A4 | |
| SCHEMBL12908000 | 0.83 | SMN1; SMN2 (0.59) | GAAKMT2APOLBMEN1LMNA | |
| SCHEMBL7044556 | 0.83 | CYP3A4 (0.55) | GAAKMT2AALDH1A1CYP1A2CYP3A4 | |
| SCHEMBL11351362 | 0.83 | ALDH1A1 (0.55) | GAAKMT2AALDH1A1CYP1A2CYP3A4 | |
| SCHEMBL11128406 | 0.82 | KMT2A (0.62) | GAAKMT2AALDH1A1MAPK1MAPT | |
| SCHEMBL654293 | 0.82 | LMNA (0.69) | GAAKMT2AALDH1A1MAPK1MAPT | |
| SCHEMBL30024728 | 0.82 | LMNA (0.69) | GAAKMT2AALDH1A1MAPK1MAPT |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 52 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20240009169-A9 | PPARG Modulators for the Treatment of Osteoporosis | UNIVERSITY OF FLORIDA RESEARCH FOUNDATION, INCORPORATED | 2024-01-11 | — | — | US | disclosed |
| US-20230331700-A1 | COMPOUND HAVING CYCLIC STRUCTURE | DAIICHI SANKYO COMPANY, LIMITED (JP) | 2023-10-19 | — | — | US | disclosed |
| US-20230072933-A1 | PPARG Modulators for the Treatment of Osteoporosis | SCRIPPS RESEARCH INST (US) | 2023-03-09 | — | — | US | disclosed |
| US-20230072933-A1 | PPARG Modulators for the Treatment of Osteoporosis | SCRIPPS RESEARCH INST (US) | 2023-03-09 | — | — | US | disclosed |
| US-20200347030-A1 | COMPOUND HAVING CYCLIC STRUCTURE | DAIICHI SANKYO COMPANY, LIMITED (JP) | 2020-11-05 | — | — | US | disclosed |
| US-10744117-B2 | PPARG modulators for the treatment of osteoporosis | THE SCRIPPS RESEARCH INSTITUTE (US) | 2020-08-18 | — | — | US | disclosed |
| US-10744117-B2 | PPARG modulators for the treatment of osteoporosis | THE SCRIPPS RESEARCH INSTITUTE (US) | 2020-08-18 | — | — | US | disclosed |
| US-20180369196-A1 | PPARG Modulators for the Treatment of Osteoporosis | UNIVERSITY OF FLORIDA RESEARCH FOUNDATION, INCORPORATED | 2018-12-27 | — | — | US | disclosed |
| US-10016394-B2 | PPARG modulators for treatment of osteoporosis | THE SCRIPPS RESEARCH INSTITUTE (US) | 2018-07-10 | — | — | US | disclosed |
| US-10016394-B2 | PPARG modulators for treatment of osteoporosis | THE SCRIPPS RESEARCH INSTITUTE (US) | 2018-07-10 | — | — | US | disclosed |
| US-7465811-B2 | Indoline compounds | LABORATOIRES FOURNIER S.A. (FR) | 2008-12-16 | — | — | US | disclosed |
| US-20080119465-A1 | Novel Indoline Compounds | LABORATORIES FOURNIER S.A. (FR) | 2008-05-22 | — | — | US | disclosed |
| US-20080119465-A1 | Novel Indoline Compounds | LABORATORIES FOURNIER S.A. (FR) | 2008-05-22 | — | — | US | disclosed |
| US-20070265291-A1 | 2,6-SUBSTITUTED-4-MONOSUBSTITUTEDAMINO-PYRIMIDINE AS PROSTAGLANDIN D2 RECEPTOR ANTAGONISTS | AVENTIS PHARMACEUTICALS INC. (US) | 2007-11-15 | — | — | US | disclosed |
| US-20070244131-A1 | 2,6-SUBSTITUTED-4-MONOSUBSTITUTEDAMINO-PYRIMIDINE AS PROSTAGLANDIN D2 RECEPTOR ANTAGONISTS | AVENTIS PHARMACEUTICALS INC. (US) | 2007-10-18 | — | — | US | disclosed |
| WO-2007000550-A2 | NOVEL INDOLINE COMPOUNDS | LABORATOIRES FOURNIER S.A. (FR) | 2007-01-04 | — | — | WO | disclosed |
| US-4455421-A | ANTIFERTILITY, ANTIULCER AGENTS; TETRAZOLE DERIVATIVES | PFIZER INC. (US) | 1984-06-19 | — | — | US | disclosed |
| US-4365077-A | ANTIFERTILITY, ANTIULCER | PFIZER INC. (US) | 1982-12-21 | — | — | US | disclosed |
| US-4157341-A | 11-Desoxy-16-aryloxy-ω-tetranorprostaglandins | PFIZER INC. (US) | 1979-06-05 | — | — | US | disclosed |
| US-4065472-A | TISSUE SPECIFICITY | PFIZER INC. (US) | 1977-12-27 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (10 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20200347030-A1 | COMPOUND HAVING CYCLIC STRUCTURE | H4C1; H4C2; H4C3; H4C4; H4C5; H4C6; H4C8; H4C9; H4C11; H4C12; H4C13; H4C14; H4C15; H4C16, ECE1, IL1B | GAA 2387/4885KMT2A 1805/4885ALDH1A1 1019/4885 |
| US-20080119465-A1 | Novel Indoline Compounds | GPR119, INSR, IRS1 | GAA 1612/4885KMT2A 1435/4885ALDH1A1 1819/4885 |
| US-10016394-B2 | PPARG modulators for treatment of osteoporosis | PPARG, PPARA, PPARD | GAA 3582/4885KMT2A 1687/4885ALDH1A1 4434/4885 |
| US-20230072933-A1 | PPARG Modulators for the Treatment of Osteoporosis | PPARG, PPARA, PPARD | GAA 3259/4885KMT2A 1302/4885ALDH1A1 4575/4885 |
| US-20180369196-A1 | PPARG Modulators for the Treatment of Osteoporosis | PPARG, PPARA, PPARD | GAA 3259/4885KMT2A 1302/4885ALDH1A1 4575/4885 |
| US-20070244131-A1 | 2,6-SUBSTITUTED-4-MONOSUBSTITUTEDAMINO-PYRIMIDINE AS PROSTAGLANDIN D2 RECEPTOR ANTAGONISTS | CYSLTR2, PTGER2, CYSLTR1 | GAA 3490/4885KMT2A 4126/4885ALDH1A1 639/4885 |
| US-10744117-B2 | PPARG modulators for the treatment of osteoporosis | PPARG, PPARA, PPARD | GAA 3259/4885KMT2A 1302/4885ALDH1A1 4575/4885 |
| US-20070265291-A1 | 2,6-SUBSTITUTED-4-MONOSUBSTITUTEDAMINO-PYRIMIDINE AS PROSTAGLANDIN D2 RECEPTOR ANTAGONISTS | CYSLTR2, PTGER2, CYSLTR1 | GAA 3490/4885KMT2A 4126/4885ALDH1A1 639/4885 |
| US-20230331700-A1 | COMPOUND HAVING CYCLIC STRUCTURE | H4C1; H4C2; H4C3; H4C4; H4C5; H4C6; H4C8; H4C9; H4C11; H4C12; H4C13; H4C14; H4C15; H4C16, ECE1, IL1B | GAA 2387/4885KMT2A 1805/4885ALDH1A1 1019/4885 |
| US-20240009169-A9 | PPARG Modulators for the Treatment of Osteoporosis | PPARG, PPARA, PPARD | GAA 3259/4885KMT2A 1302/4885ALDH1A1 4575/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.